ARTICLE | Finance
Jan. 3 Quick Takes: Goldman Sachs unveils $650M life sciences fund
Plus: Arrowhead trades up as $450M follow-on extends runway and updates from Remix, CG Oncology, Agios, Boehringer-Ribo, Enyo
January 4, 2024 1:44 AM UTC
Goldman Sachs debuted the first fund in its life sciences investing strategy, the $650 million West Street Life Sciences I fund. Led by Amit Sinha, Goldman’s head of life sciences investing, the private growth fund will invest in early to mid-stage therapeutics companies pursuing multiple assets as well as tools and diagnostics companies, with a focus on precision and genetic medicine, cell therapy, immunotherapy, synthetic biology and AI.
The new fund has invested about $90 million across five portfolio companies to date: oncology companies MOMA Therapeutics Inc., Nested Therapeutics Inc. and Torl BioTherapeutics LLC, neurology play Rapport Therapeutics Inc., and GPCR drug discovery biotech Septerna Inc...